Select Language
Her2
Her2 Overview
| English Name | Receptor protein-tyrosine kinase erbB-2 | Approved Drugs | 48 |
| Drugs in Clinical Trials | 229 | Target Synonym | EC 2.7.10.1，HER-2/Neu，Herstatin，HER-2，TKR1，Receptor， ErbB-2，V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2， Neuro/Glioblastoma Derived Oncogene Homolog，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2，Neuroblastoma/Glioblastoma Derived Oncogene Homolog，C-Erb B2/Neu Protein，CD340 Antigen，EC:2.7.10.1，EC 2.7.10，MLN 19，CD340，Tyrosine kinase-type cell surface receptor HER2，Receptor tyrosine-protein kinase erbB-2，ERBB2，MLN19，Proto-oncogene Neu，Erb-B2 Receptor Tyrosine Kinase 2，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2，Neuro/Glioblastoma Derived Oncogene Homolog，Human Epidermal Growth Factor Receptor 2，Metastatic Lymph Node Gene 19 Protein，Proto-Oncogene C-ErbB-2，P185erbB2，HER2，NGL，NEU，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (Neuro/Glioblastoma Derived Oncogene Homolog) |
| Highest Development Stage | Approved | ||
| English Name | Receptor protein-tyrosine kinase erbB-2 |
| Target Synonym | EC 2.7.10.1，HER-2/Neu，Herstatin，HER-2，TKR1，Receptor， ErbB-2，V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2， Neuro/Glioblastoma Derived Oncogene Homolog，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2，Neuroblastoma/Glioblastoma Derived Oncogene Homolog，C-Erb B2/Neu Protein，CD340 Antigen，EC:2.7.10.1，EC 2.7.10，MLN 19，CD340，Tyrosine kinase-type cell surface receptor HER2，Receptor tyrosine-protein kinase erbB-2，ERBB2，MLN19，Proto-oncogene Neu，Erb-B2 Receptor Tyrosine Kinase 2，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2，Neuro/Glioblastoma Derived Oncogene Homolog，Human Epidermal Growth Factor Receptor 2，Metastatic Lymph Node Gene 19 Protein，Proto-Oncogene C-ErbB-2，P185erbB2，HER2，NGL，NEU，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (Neuro/Glioblastoma Derived Oncogene Homolog) |
| Approved Drugs | 48 |
| Drugs in Clinical Trials | 229 |
| Highest Development Stage | Approved |
Her2 Product List
- Product Category
Protein (34)Kits (1)Beads (1)Antibody (2)Cell Grade Beads (1)Cell (1)
- Product Status
Launched (40)
- Species
Human (27)Mouse (5)Cynomolgus (4)Rabbit (2)Rat (2)
- Tag
His Tag (18)Fc Tag (6)Strep Tag (1)His Tag & Avi Tag (4)- (6)Tag Free (2)Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (2)
- Conjugate
Unconjugated (20)Biotin-labeled (7)- (4)FITC Labeled (2)PE Labeled (2)APC Labeled (2)AF647 Labeled (1)AF555 Labeled (1)AF488 Labeled (1)
Total: 40
- 1
- 2
- 3
- 4
Her2 Background
Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .
Her2 Synonyms
ERBB2,CD340,HER-2,neu,HER2,MLN19,NEU,NGL,TKR1
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
| Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase 3 Clinical | Shanghai Institute of Biological Products Co Ltd | Breast Neoplasms; Stomach Neoplasms | Details |
| Anvatabart opadotin | NCB-001; JNJ-0683; ARX-788 | Phase 3 Clinical | Ambrx Inc | Bile Duct Neoplasms; Breast Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Sacibertinib | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | Details |
| Pertuzumab biosimilar（Hisun Pharm） | HS-627; HS627 | Phase 3 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Recombinant human neuregulin-1 | rhNRG-1 | Phase 3 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Myocardial Infarction | Details |
| Caxmotabart Entudotin | FS-1502; LCB14-0110; LCB-14-0110; IKS014; IKS-014; LCB-14 | Phase 3 Clinical | Legochembio | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | Details |
| HLX-22 | AC-101; HLX-22; HLX22 | Phase 3 Clinical | Atlas Therapeutics AB | Breast Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Coprelotamab | GB-221 | Phase 3 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab vedotin | MRG-002 | Phase 3 Clinical | Shanghai Miracogen Inc | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | Details |
| trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase 3 Clinical | Hetero Drugs Ltd | Neoplasms | Details |
| T‑Bren | BLM07D1; BL-M07D1 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms | Details |
| Pertuzumab biosimilar(Zydus Cadila) | ZRC-3277 | Phase 3 Clinical | Zydus Cadila | Metastatic breast cancer | Details |
| HL-02 | HL-02 | Phase 3 Clinical | Hualan Ankang Biotechnology Co Ltd | Breast Neoplasms | Details |
| JSKN-003 | JSKN-003 | Phase 3 Clinical | Alphamab Oncology | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Diseases; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Trastuzumab biosimilar (Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Breast Neoplasms | Details | |
| Ado Trastuzumab Emtansine biosimilar (Hetero Biopharma) | HBP 6 | Phase 3 Clinical | Hetero Biopharma Ltd | Breast Neoplasms | Details |
| IBI-354 | IBI-354 | Phase 3 Clinical | Breast Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Ovarian Diseases; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Solid tumours | Details | |
| TQB-2102 | TQB2102; TQB-2102 | Phase 3 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| TQB-2930 | TQB-2930 | Phase 3 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Breast Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours | Details |
| HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) | GLSI-100 | Phase 3 Clinical | Antigen Express Inc, Norwell Inc | Breast Neoplasms | Details |
| Trastuzumab pamirtecan | DB-1303; BNT323 | Phase 3 Clinical | Duality Biologics (Suzhou) Co Ltd | Breast Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Solid tumours | Details |
| GQ-1005 | GQ-1005; GQ1005 | Phase 3 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Trastuzumab biosimilar(Aprogen/Nichi-Iko) | AP-06 | Phase 3 Clinical | Aprogen, Nichi-Iko Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar (Xuanzhu/SL) | KM-118; KM118; XZP-KM118 | Phase 3 Clinical | Beijing Sl Pharmaceutical Co Ltd, Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Breast Neoplasms | Details | |
| IAH-0968 | IAH0968; IAH-0968 | Phase 3 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Biliary Tract Neoplasms; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BAT-1006 | BAT-1006 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Breast Neoplasms; Solid tumours | Details |
| Trastuzumab envedotin | DP-303c; DP303c; SYSA1501; SYSA-1501 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Breast Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Salivary Gland Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours | Details |
| DF-1001 | DF-1001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| TPIV-100 (TapImmune) | TPIV-100 | Phase 2 Clinical | Mayo Clinic | Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating | Details |
| BB-1701 | BB-1701 | Phase 2 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | Huazhong University Of Science And Technology, Medimmune, University Of Michigan, University Of Virginia Cancer Center | Breast Neoplasms | Details | |
| RG-6596 | ZN-1041; RG-6596; ZN-A-1041 | Phase 2 Clinical | Suzhou Zanrong Pharmaceutical Technology Co Ltd | Breast Neoplasms; Solid tumours | Details |
| AU-101 | AU-101 | Phase 2 Clinical | Attralus Inc | Breast Neoplasms; Glioblastoma; Osteosarcoma | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive | Details |
| DX126-262 | DAC-001; DX126-262 | Phase 2 Clinical | Hangzhou Dac Biotech Company Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Metastatic breast cancer; Stomach Neoplasms | Details |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Breast Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| AU-105 | AU-105 | Phase 2 Clinical | Attralus Inc | Glioblastoma | Details |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 2 Clinical | Array Biopharma | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| HER2 cancer vaccine (BioLife Science) | PEV-6; PEV-6A; IMU-131 | Phase 2 Clinical | Pevion Biotech Ltd | Adenocarcinoma; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Stomach Neoplasms | Details |
| AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase 2 Clinical | Generex Biotechnology Corp | Breast Neoplasms; Triple Negative Breast Neoplasms | Details |
| ADXS-31164 | Lovaxin B; OST-HER2; OST31-164; ADXS31-164; ADXS-31164; ADXS-cHER2; ADXS-HER2 | Phase 2 Clinical | University Of Pennsylvania | Bone Neoplasms; Solid tumours | Details |
| Enozertinib | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Nesfrotamig | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| EB-DT-CAR-NK | EB-DT-CAR-NK | Phase 2 Clinical | Beijing Biotech | Breast Neoplasms; Triple Negative Breast Neoplasms | Details |
| EB-DuoNK-MSLN/HER2 cell therapy (Beijing Biotech) | Phase 2 Clinical | Beijing Biotech | Carcinoma, Non-Small-Cell Lung | Details | |
| HER2 FPBMC therapy (University Of Virginia) | HER2 FPBMC | Phase 2 Clinical | University Of Virginia | Breast Neoplasms; Prostatic Neoplasms | Details |
| CLIO-8221 | HMBD-802; HMBD802; CLIO8221; CLIO-8221 | Phase 2 Clinical | Hummingbird Bioscience | Solid tumours | Details |
| 99mTc-ZHER2:41071 | Phase 2 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details | |
| 68-GaNOTA-Anti-HER2 VHH1 | Phase 2 Clinical | Universitair Ziekenhuis Brussel | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms; Salivary Gland Neoplasms; Stomach Neoplasms; Uterine Neoplasms | Details | |
| HMPL-A251 | HMPLA251; HMPL-A251 | Phase 2 Clinical | Solid tumours | Details | |
| Pertuzumab biosimilar (Peking Union Medical College Hospital) | Phase 2 Clinical | Peking Union Medical College Hospital | Rectal Neoplasms | Details | |
| Trastuzumab biosimilar (Peking Union Medical College Hospital) | Phase 2 Clinical | Peking Union Medical College Hospital | Rectal Neoplasms | Details | |
| HER2 targeting chimeric antigen receptor T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Osteosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Kaposi; Sarcoma, Synovial | Details | |
| SYS-6045 | SYS6045; SYS-6045 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours | Details |
| YH-42946 | YH42946; YH-42946 | Phase 2 Clinical | Yuhan Corp | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours; Uterine Neoplasms | Details |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| SHR-4602 | SHR-4602; SHR4602 | Phase 2 Clinical | Shanghai Suncadia Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours | Details |
| HER2 Targeted HypoSti.CAR-T Cells(Chinese PLA General Hospital) | Phase 2 Clinical | Fudan University, Pla General Hospital | Solid tumours | Details | |
| FDA022 Antibody Drug Conjugate | FDA022-BB05; F0034 | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours | Details |
| I-025-A | I-025-A | Phase 2 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms; Colorectal Neoplasms | Details |
| BAT-8010 | BAT-8010; BAT8010 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| RAD-201 | RAD-201 | Phase 2 Clinical | Radiopharm Theranostics Ltd | Breast Neoplasms | Details |
| ST-1703 | ST-1703 | Phase 2 Clinical | Beijing Scitech-Mq Pharmaceuticals Ltd | Metastatic breast cancer; Solid tumours | Details |
| TL-938 | TL-938 | Phase 2 Clinical | Suzhou Teligene Ltd | Colorectal Neoplasms; Neoplasms | Details |
| SSGJ-705 | SSGJ-705; 705 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Neoplasms; Solid tumours | Details |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
| SPH-5030 | SPH-5030 | Phase 2 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Colorectal Neoplasms; Solid tumours | Details |
| IMM-2902 | IMM-2902 | Phase 2 Clinical | Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) | HuA21; HuA-21 | Phase 2 Clinical | Hefei Hankemab Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| AIP-303 | AIP-303 | Phase 2 Clinical | Advanced Imaging Projects | Breast Neoplasms | Details |
| GQ-1001 | GQ-1001 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Metastatic breast cancer; Solid tumours | Details |
| Epertinib | S-222611; RT1978; RT-1978 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| Gancotamab | MM-302 | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Breast Neoplasms; Ovarian Neoplasms | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Bone metastases; Breast Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
| anti-HER2 ADC (Pfizer) | PF-06804103 | Phase 2 Clinical | Pfizer Inc | Breast Neoplasms; Neoplasms; Triple Negative Breast Neoplasms | Details |
| ETBX-021 | ETBX-021 | Phase 2 Clinical | Etubics Corp, Nantbioscience Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase 1 Clinical | City Of Hope National Medical Center, Mustang Bio Inc | Glioma | Details | |
| RG-6148 | RG-6148; DHES-0815A | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms | Details |
| CIDeCAR | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, National Cancer Institute | Osteosarcoma | Details | |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Carcinoma; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Desmoplastic Small Round Cell Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Clear Cell; Sarcoma, Ewing; Sarcoma, Synovial; Solid tumours; Wilms Tumor | Details | |
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase 1 Clinical | Nanomab Technology Ltd | Breast Neoplasms | Details |
| GB-235 | GB-235 | Phase 1 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) | Phase 1 Clinical | National Cancer Institute, University Of Pennsylvania | Breast Neoplasms | Details | |
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| TAS-0728 | TPC-107; TAS-0728 | Phase 1 Clinical | Taiho Pharmaceutical Co Ltd | Solid tumours | Details |
| 68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) | Phase 1 Clinical | Universite Libre De Bruxelles | Breast Neoplasms | Details | |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) | LZM-005 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Breast Neoplasms | Details |
| MX-402 | MX-402 | Phase 1 Clinical | Medvax Technologies | Stomach Neoplasms | Details |
| MB-103 | MB-103 HER2 CAR; MB-103; HER2(EQ)BBζ/CD19t+ Tcm; HER2-BBζ CAR-T cells | Phase 1 Clinical | City Of Hope National Medical Center | Brain metastases; Breast Neoplasms; Glioblastoma; Meningeal Neoplasms; Neoplasms | Details |
| Fidasimtamab | IBI-315; BH-2950 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Breast Neoplasms; Stomach Neoplasms | Details | |
| Recombinant anti-HER2 humanized monoclonal antibody complex | B-002 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
| Runimotamab | RO-7227780; BTRC-4017A; RG-6194 | Phase 1 Clinical | Genentech Inc | Solid tumours | Details |
| KSP-910638-G | KSP-910638G; KSP-910638-G | Phase 1 Clinical | University Of Michigan | Gastrointestinal Neoplasms | Details |
| TT-16 | TT-16 | Phase 1 Clinical | Tessa Therapeutics Ltd | Solid tumours | Details |
| Ado-trastuzumab emtansine biosimilar (Jiangsu Hengrui Medicine) | SHR-A1201 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Breast Neoplasms | Details |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Breast Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase 1 Clinical | Baylor College Of Medicine | Brain Neoplasms; Sarcoma | Details |
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | HS-630; HS630 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Research Institute | Central Nervous System Neoplasms | Details | |
| [89Zr]-Df-Trastuzumab | Phase 1 Clinical | University Of Alabama At Birmingham | Breast Neoplasms; Neoplasms; Solid tumours | Details | |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| Pertuzumab biosimilar(SL Pharma/Combio) | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd | Breast Neoplasms; Inflammatory Breast Neoplasms; Metastatic breast cancer | Details | |
| ZV-0203 | ZV-0203; ZV203; ADC2122; ZV0203; ADC 2122 | Phase 1 Clinical | Hangzhou Adcoris Biopharmacy Co Ltd | Solid tumours | Details |
| 4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma; Neoplasms | Details | |
| HER2.taNK | NK-92/5.28.z | Phase 1 Clinical | Nantkwest Inc | Glioblastoma | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase 1 Clinical | Biointegrator Llc | Breast Neoplasms | Details |
| BAY-2701438 | BAY-2701438 | Phase 1 Clinical | Bayer AG | Neoplasms | Details |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Stomach Neoplasms | Details | |
| GB-251 | GB-251; NBT-828; GB221-NBT828 ADC-1 | Phase 1 Clinical | Genor Biopharma Co Ltd, Newbio Therapeutics Inc | Breast Neoplasms; Metastatic breast cancer | Details |
| HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Glioblastoma | Details |
| ALT-P7 | HM2-MMAE; ALT-P7 | Phase 1 Clinical | Alteogen Inc | Breast Neoplasms; Stomach Neoplasms | Details |
| Trastuzumab imbotolimod | BDC-1001; Boltbody™ ISAC BDC-1001 | Phase 1 Clinical | Bolt Biotherapeutics Inc | Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours | Details |
| anti-HER2 CAR macrophage therapy (The Affiliated Hospital of Xuzhou Medical University) | Phase 1 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms | Details | |
| anti-HER2 CAR T-cell therapy (Shanghai First Song Therapeutics) | Phase 1 Clinical | Shanghai Simcere Pharmaceutical Co Ltd | Colorectal Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| EX-101 (Excelmab) | Phase 1 Clinical | ExcelMab Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| MHC class II HER-2/neu antigen vaccine (Marker Therapeutics) | Phase 1 Clinical | Mayo Clinic | Breast Neoplasms | Details | |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms | Details | |
| SHR-1904 | SHR-1904 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Pancreatic Neoplasms; Solid tumours | Details |
| [177Lu]Lu-ABY-271 | 177Lu-ABY-271 | Phase 1 Clinical | Affibody Medical AB | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Metastatic breast cancer; Ovarian Neoplasms; Stomach Neoplasms | Details |
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Adenocarcinoma; Breast Neoplasms; Neoplasm Metastasis; Neoplasms | Details | |
| VRN-10 | VRN-101099; VRN-10 | Phase 1 Clinical | Voronoi Inc | Neoplasms; Solid tumours | Details |
| NC-18 | NC-18 | Phase 1 Clinical | Novacyte Therapeutics Company Ltd | Solid tumours | Details |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Breast Neoplasms; Solid tumours | Details |
| Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase 1 Clinical | United Biopharma Inc | Breast Neoplasms | Details |
| TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Neoplasms | Details |
| NeuCeptin | NeuCeptin | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Breast Neoplasms; Stomach Neoplasms | Details |
| SAR-446309 | AMX-818; HER2-XPAT; SAR-446309; VIR-5818 | Phase 1 Clinical | Amunix Pharmaceuticals Inc | Neoplasms; Solid tumours | Details |
| XMT-2056 | XMT-2056 | Phase 1 Clinical | Mersana Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Stomach Neoplasms | Details |
| EB-DT-NK-UC101 | EB-DT-NK-UC101 | Phase 1 Clinical | Beijing Biotech | Carcinoma; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms | Details |
| CAN-016 | CAN016; CAN-016 | Phase 1 Clinical | Conway (Guangzhou) Biotechnology Co Ltd | Solid tumours | Details |
| Bmab-3000 | Bmab3000; Bmab-3000 | Phase 1 Clinical | Biocon Biologics UK Plc | Details | |
| CGT-4255 | CGT-4255; CGT4255 | Phase 1 Clinical | Cogent Biosciences Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| 68Ga-SNA018 | 68Ga-SNA018; 68Ga-SNA-018; 68Ga-ADAPT6 | Phase 1 Clinical | Kth Royal Institute Of Technology, Uppsala University | Breast Neoplasms; Stomach Neoplasms | Details |
| RR-M01 | RR-M01; BM-1901 | Phase 1 Clinical | Rock Roc Biotechnology Co Ltd | Solid tumours | Details |
| 68Ga SGMIB-ZT-199 | 68Ga-SGMIB-ZT-199 | Phase 1 Clinical | Huashan Hospital | Breast Neoplasms | Details |
| 188Re-NM-02 | 188Re-NM-02 | Phase 1 Clinical | NanoMab Technology (UK) Ltd, Shanghai Jiao Tong University Affiliated First People'S Hospital | Breast Neoplasms | Details |
| 89Zr-LNCab072 | 89Zr-LNCab072 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | Details |
| 89Zr-LNCab002 | 89Zr-LNCab002 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | Details |
| 89Zr-LNCab190 | 89Zr-LNCab190 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | Details |
| 89Zr-LNCab104 | 89Zr-LNCab104 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | Details |
| 89Zr-LNCab103 | 89Zr-LNCab103 | Phase 1 Clinical | Affiliated Hospital of Jiangnan University | Breast Neoplasms; Carcinoma, Transitional Cell; Stomach Neoplasms | Details |
| [111In]In-DOTA-TCO-trastuzumab | Phase 1 Clinical | Radboud University Medical Center | Solid tumours | Details | |
| TGW-211 | TGW-211; TRG001; TRG-001 | Phase 1 Clinical | Tagworks Pharmaceuticals BV | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| AK-2024 | AK2024; AK-2024; BSI-128 | Phase 1 Clinical | Biosion Inc | Solid tumours | Details |
| SYS-6040 | SYS6040; SYS-6040 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| 177 Lu-RAD202 | 177 Lu-RAD202 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| GenSci-139 | GenSci-139; GenSci139 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Zanidatamab zovodotin | ZW-49 | Phase 1 Clinical | Zymeworks Inc | Neoplasms | Details |
| SYS-6041 | SYS6041; SYS-6041 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms | Details |
| BL-M17D1 | BL-M17D1; BL-M217D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Metastatic breast cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| NVL-330 | NVL-330 | Phase 1 Clinical | Nuvalent Inc | Neoplasms; Solid tumours | Details |
| IAM-1363 | IAM-H1; ENT-H1; IAM1363; IAM-1363 | Phase 1 Clinical | Iambic Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Human HER2-targeted CAR-M cells therapy (Macera therapeutics) | Phase 1 Clinical | Nanjing Yuanmai Cell Biotechnology Co Ltd | Stomach Neoplasms | Details | |
| AB-201(GC Cell) | Phase 1 Clinical | GC Cell Corp | Neoplasms | Details | |
| MSH-2IA | MSH2IA; MSH-2IA | Phase 1 Clinical | Imagion Biosystems Ltd | Breast Neoplasms | Details |
| SIBP-A17 | SIBP-A17; SIBPA17 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours | Details |
| Anti-HER2-CAR-T Cells Therapy(First Song Therapeutics) | Phase 1 Clinical | China Medical University, China, Shanghai First Song Therapeutics Co Ltd | Solid tumours | Details | |
| [68Ga]ABY-025 | ABY-025; 68GaABY025; [68Ga]-ABY-025; ABY-025-[68Ga]; Gallium-68-ABY-025; [68Ga]Ga-ABY-025 PET | Phase 1 Clinical | Affibody Ab | Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasm Metastasis; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| 89Zr-DFO*Trastuzumab | Phase 1 Clinical | Astrazeneca Plc | Breast Neoplasms; Metastatic breast cancer; Stomach Neoplasms | Details | |
| [123I] I-(HE)3-G3 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details | |
| D3L-001 | D3L-001 | Phase 1 Clinical | D3 Bio (Wuxi) Co Ltd | Neoplasms; Solid tumours | Details |
| KY-1702 | KY-1702; KY1702 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
| XZP-KM501 | XZP-KM501; KM-501 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| SMP-656 | SMP-656 | Phase 1 Clinical | Chengdu Xilinglab Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| ELVN-002 | ELVN-002 | Phase 1 Clinical | Enliven Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | Details |
| CPO-204 | CPO-204 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Carcinoma, Transitional Cell | Details |
| 99mTc-MIRC213 | 99-mTc-MIRC-213 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
| TY4028 | TY-4028; TY4028 | Phase 1 Clinical | TYK Medicines Inc | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| FT-825 | ONO-8250; FT-825; ONO 8250/FT 825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Solid tumours | Details |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
| Allogeneic blood-derived NK cell therapy (NKGen Biotech) | SNK-02; SNK02; CAR-SNK-02 | Phase 1 Clinical | NKGen Biotech Inc | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| KMHH-03 | KMHH-03; KMHH03 | Phase 1 Clinical | Beijing Kangming Haihui Biological Technology Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar (biocad) | BCD-178 | Phase 1 Clinical | BIOCAD JSC | Breast Neoplasms | Details |
| 99mTc- ADAPT6 | 99mTc- ADAPT6; ADAPT6; SNA-018; 99mTc-SNA-018 | Phase 1 Clinical | Kth Royal Institute Of Technology, Uppsala University | Breast Neoplasms | Details |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3; 99mTc-(CO)3-(HE)3-Ec1; [99mTc]Tc(CO)3-(HE)3-Ec1 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms; Solid tumours | Details |
| 227Th-Trastuzumab corixeta | BAY-2701439 | Phase 1 Clinical | Bayer AG | Neoplasms | Details |
| XZP-KM257 | XZP-KM257; KM-257 | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd | Solid tumours | Details |
| PM-3002 | PM-3002 | Phase 1 Clinical | Details | ||
| XZP-5209 | XZP-5209 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Breast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) | Phase 1 Clinical | Baylor College Of Medicine, Texas Children'S Hospital, The Hospital For Sick Children, The Methodist Hosp Research Institute | Sarcoma | Details | |
| HER-2 Specific CAR T Cell | Phase 1 Clinical | Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital | Ependymoma | Details | |
| AB-201 (Artiva Biotherapeutics) | GCC2003; AB-201 (Artiva Biotherapeutics); GCC-2003 | Phase 1 Clinical | GC Cell Corp | Breast Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| 89Zr-ss-Pertuzumab | Phase 1 Clinical | Genentech Inc | Breast Neoplasms; Metastatic breast cancer | Details | |
| SSGJ-612 | SSGJ-612 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Neoplasms; Solid tumours | Details |
| Pertuzumab biosimilar(EirGenix) | EG-1206A; EG-1206-A | Phase 1 Clinical | Eirgenix Inc | Breast Neoplasms | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
| CT-0508 | CT-0508 | Phase 1 Clinical | Carisma Therapeutics Inc | Solid tumours | Details |
| CCT303-406 | CCT3-HER2-0406; CCT303-406 | Phase 1 Clinical | BioAtla Inc | Breast Neoplasms; Ovarian Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| DZD-1516 | DZD-1516 | Phase 1 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
| MBS-301 | MBS-301 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FCN-411 | FCN-411 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details | |
| ACE-1702 | ACE-1702 | Phase 1 Clinical | Acepodia Taiwan Subsidiary | Metastatic breast cancer; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | Details |
| CX510 | CX510; CX-510 | Phase 1 Clinical | Hangzhou Aojin Biomedical Technology Co Ltd, Hangzhou Sanyintai Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Breast Neoplasms | Details | |
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
| Trastuzumab biosimilar (BioXpress) | BXT-2318; BX-2318 | Clinical | Bioxpress Therapeutics Sa | Metastatic breast cancer; Stomach Neoplasms | Details |
| IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Clinical | Inbiopro Solutions | Breast Neoplasms | Details |
| 99-mTc-ABH-2 | Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details | |
| IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Clinical | Inbiopro Solutions | Carcinoma, Renal Cell; Colorectal Neoplasms; Small Cell Lung Carcinoma | Details |
| 131I SGMIB-ZT-199 | 131I-SGMIB-ZT-199 | Clinical | Huashan Hospital | Breast Neoplasms | Details |
| 18F-HER2 PET | Clinical | First Affiliated Hospital Of Zhejiang University | Carcinoma, Transitional Cell | Details | |
| [18F]F-RESCA-RB14 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | Details | |
| [68Ga]Ga-DOTA-H2D3 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | Details | |
| 68Ga-Her2-affibody | 68Ga-Her2-affibody | Clinical | The First Affiliated Hospital Of Beijing University | Neoplasms | Details |
| Anti-HER2 CAR-T cell therapy (UTC Therapeutics) | Clinical | UTC Therapeutics Inc | Solid tumours | Details | |
| 99mTc-DARPinG3 | 99mTc-DARPinG3; 99mTc-DARPinG-3 | Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details |
| 99mTc-MIRC208 | Clinical | Beijing Cancer Hospital | Neoplasms | Details | |
| [18F]GE-226 | GE-226-[18F]; Fluorine-18-GE-226; [18F]GE-226; 18F-GE-226 | Clinical | Affibody Ab | Breast Neoplasms | Details |
| GW-2974 | GW-2974 | Glaxosmithkline Plc | Neoplasms | Details | |
| [99mTc]Tc-G3-(G3S)3C | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Trastuzumab biosimilar (Celltrion) | CT-P6; CT-P06 | Approved | Celltrion Inc | Herzuma | South Korea | Stomach Neoplasms; Breast Neoplasms | null | 2014-01-01 | Breast Neoplasms; Metastatic breast cancer; Stomach Neoplasms | Details |
| Trastuzumab emtansine biosimilar (Zydus Cadila) | ZRC-3256 | Approved | Zydus Cadila | Ujvira | India | Breast Neoplasms | Zydus Cadila | 2021-05-24 | Breast Neoplasms | Details |
| Zanidatamab | JZP-598; ZW-25 | Approved | Zymeworks Inc | Ziihera, 百赫安 | United States | Biliary Tract Neoplasms | Jazz Pharmaceuticals Inc, Jazz Pharmaceuticals Plc | 2024-11-20 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Salivary Gland Neoplasms; Sarcoma; Stomach Neoplasms | Details |
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞泽 | Mainland China | Stomach Neoplasms; Breast Neoplasms | Hisun Biopharmaceutical Co Ltd | 2023-02-28 | Breast Neoplasms; Stomach Neoplasms | Details |
| Trastuzumab biosimilar (Samsung Bioepis) | AMT-901; SB-3 | Approved | Samsung Bioepis Co Ltd | Samfenet, Ontruzant | EU | Breast Neoplasms; Stomach Neoplasms | Samsung Bioepis Nl Bv | 2017-11-15 | Breast Neoplasms; Stomach Neoplasms | Details |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Diseases; Lung Neoplasms; Lymphoma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Squamous Cell; Neuroectodermal Tumors; Penile Squamous Cell Carcinoma; Prostatic Neoplasms; Renal Insufficiency; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Neoplasms | Details |
| Trastuzumab biosimilar (Synthon) | ABP-980 | Approved | Synthon Bv | Kanjinti | EU | Breast Neoplasms; Stomach Neoplasms | Amgen Europe Bv | 2018-05-16 | Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Mifanertinib Maleate | MET-306 | Approved | Suzhou Maitai Bio-Technology Co Ltd | 迈瑞东 | Mainland China | Carcinoma, Non-Small-Cell Lung | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | 2025-10-21 | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Trastuzumab biosimilar (Zydus) | Approved | Zydus Cadila | Vivitra | India | Breast Neoplasms | Zydus Cadila | 2016-01-01 | Breast Neoplasms | Details | |
| Margetuximab | MGAH-22 | Approved | Raven Biotechnologies Inc | Margenza | United States | Breast Neoplasms | Macrogenics Inc | 2020-12-16 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Trastuzumab/Pertuzumab | RO-7198574; RG-6264 | Approved | F. Hoffmann-La Roche Ltd | Phesgo, 赫捷康 | United States | Breast Neoplasms | Genentech Inc | 2020-06-29 | Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | TrastuRel | India | Breast Neoplasms | Reliance Life Sciences | 2015-01-01 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Anke Biotech) | Approved | Anhui Anke Biotechnology (Group) Co Ltd | Mainland China | Breast Neoplasms | Anhui Anke Biotechnology (Group) Co Ltd | 2023-10-27 | Breast Neoplasms | Details | ||
| Trastuzumab biosimilar (Hanwha Biologics) | HD-201 | Approved | Hanwha Biologics | Tuznue, Hervelous | EU | Breast Neoplasms; Stomach Neoplasms | Prestige BioPharma Ltd | 2024-09-19 | Breast Neoplasms; Stomach Neoplasms | Details |
| Inetetamab | CMAB-302; 302(3SBio); 302H | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Cipterbin, 赛普汀 | Mainland China | Breast Neoplasms | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 2020-06-17 | Breast Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab biosimilar (Pfizer) | PF-5280014; PF-05280014 | Approved | Pfizer Inc | Trazimera, trastuzumab-qyyp | EU | Breast Neoplasms; Stomach Neoplasms | Pfizer Europe Ma Eeig | 2018-07-26 | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Trastuzumab biosimilar (Alteogen) | ALT-L2; ALT-02; QL-1701; ALT-LS2 | Approved | Alteogen Inc | Mainland China | Breast Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-06-28 | Breast Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Stomach Neoplasms | Details | |
| Trastuzumab biosimilar (CTTQ Pharma) | TQ-B211 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 赛妥 | Mainland China | Breast Neoplasms; Stomach Neoplasms | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-07-25 | Breast Neoplasms; Metastatic breast cancer; Stomach Neoplasms | Details |
| Trastuzumab biosimilar (AXXO) | Approved | Axxo | Breast Neoplasms | Details | ||||||
| Trastuzumab rezetecan | SHR-A1811 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾维达 | Mainland China | Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2025-05-27 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; HR-positive breast cancer; Lymphangioma, Cystic; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon Ltd, Mylan Nv | CANMAb, Ogivri, Zedora, Hertraz | India | Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms | null | 2013-01-01 | Breast Neoplasms; Carcinoma, Ductal, Breast; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Trastuzumab botidotin | A-166 | Approved | Sichuan Kelun Pharmaceutical Co Ltd | 舒泰莱 | Mainland China | Breast Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2025-10-14 | Bile Duct Neoplasms; Breast Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Mucinous; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Metastatic breast cancer; Mouth Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rare Diseases; Rectal Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Solid tumours; Stomach Neoplasms; Tongue Neoplasms; Tonsillar Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Trastuzumab | R-597; RO45-2317; Anti-HER2/neu-MAb; huMAb4D5-8; RG-597; MKC-454 | Approved | Genentech Inc | Herceptin, 赫赛汀 | United States | Breast Neoplasms | Genentech Inc | 1998-09-25 | Adenocarcinoma; Breast Diseases; Breast Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Endometrial Neoplasms; Ependymoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Meningeal Carcinomatosis; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Neoplastic Cells, Circulating; Prostatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vulvar Diseases | Details |
| Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast Neoplasms | Details | ||||||
| Tucatinib | ARRY-380; ONT-380; MK-7119 | Approved | Array Biopharma | Tukysa | United States | Breast Neoplasms | Seagen Inc | 2020-04-17 | Breast Neoplasms; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hepatic Insufficiency; Meningeal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms | Details |
| Ado-trastuzumab emtansine | RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 | Approved | Genentech Inc | Kadcyla, 赫赛莱 | United States | Breast Neoplasms | Genentech Inc | 2013-02-22 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Metastatic breast cancer; Multiple Myeloma; Neoplasm Metastasis; Pancreatic Neoplasms; Salivary Gland Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
| Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Hervycta | India | Breast Neoplasms | Dr.Reddy's Laboratories Ltd | 2018-07-26 | Breast Neoplasms | Details | |
| Zenocutuzumab | MCLA-128 | Approved | Merus Nv | Bizengri | United States | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Merus Nv | 2024-12-04 | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| Pertuzumab | rhuMab-2C4; RO-4368451; R-1273; RG-1273; RO-4368451-F01; rhuMAb2C4; Ro 436-8451/F01; RO4368451 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | 帕捷特, Perjeta, Omnitarg | United States | Breast Neoplasms | Genentech Inc | 2012-06-08 | Adrenal Gland Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Multiple Endocrine Neoplasia; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Trastuzumab/Hyaluronidase | Approved | Genentech Inc | Herceptin Hylecta | United States | Breast Neoplasms | Genentech Inc | 2019-02-28 | Breast Neoplasms | Details | |
| Fam-trastuzumab deruxtecan | DS-8201a; DS-8201; VRN-101099; T-DXd | Approved | Daiichi Sankyo Co Ltd | Enhertu, 优赫得, 優赫得 | United States | Breast Neoplasms | Daiichi Sankyo Co Ltd | 2019-12-20 | Adenocarcinoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Meningeal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Neoplasms, Glandular and Epithelial; Osteosarcoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | Approved | Zercepac, 汉曲优, HERCESSI | EU | Breast Neoplasms; Stomach Neoplasms | Accord Healthcare Slu | 2020-07-27 | Breast Neoplasms; Neoplasms; Stomach Neoplasms | Details | |
| Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | BIOCAD JSC | HERtiCAD | Russian Federation | Breast Neoplasms | BIOCAD JSC | 2016-01-01 | Breast Neoplasms | Details |
| Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11 | Approved | POHERDY | United States | Breast Neoplasms | Shanghai Henlius Biologics Co Ltd, Shanghai Henlius Biotech Inc | 2025-11-13 | Breast Neoplasms; Metastatic breast cancer | Details | |
| Pertuzumab biosimilar (Hisun Biopharma) | Approved | Hisun Biopharmaceutical Co Ltd | 贝泽汀 | Mainland China | Breast Neoplasms | Hisun Biopharmaceutical Co Ltd | 2026-02-02 | Breast Neoplasms | Details | |
| Trastuzumab biosimilar(Curateq Biologics) | BP02; BP-02 | Approved | CuraTeQ Biologics Pvt Ltd | EU | Stomach Neoplasms; Breast Neoplasms | CuraTeQ Biologics SRO | 2025-06-30 | Breast Neoplasms; Neoplasms; Stomach Neoplasms | Details | |
| Neratinib Maleate | HKI-272; PF-0528767; WAY-179272; CAN-030; PB-272 | Approved | Pfizer Inc | Nerlynx, 贺俪安, 汉奈佳, 赫赛佳, Hernera | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Abdominal Neoplasms; Adenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Central Nervous System Neoplasms; CNS Embryonal Tumor; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Lip Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Medulloblastoma; Melanoma; Metastatic breast cancer; Mouth Neoplasms; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Gonadal Tissue; Neurofibromatosis 2; Neuroma, Acoustic; Nose Neoplasms; Oligoden | Details |
| Trastuzumab biosimilar (EirGenix/Sandoz) | EG-12014; EGI 014A1; EGI-014 | Approved | Eirgenix Inc, Sandoz | EU | Breast Neoplasms; Stomach Neoplasms | Sandoz Gmbh | 2023-11-15 | Breast Neoplasms; Stomach Neoplasms | Details | |
| Sevabertinib | BAY-2927088 | Approved | Bayer AG, Broad Institute, Harvard University | Hyrnuo | United States | Carcinoma, Non-Small-Cell Lung | Bayer Healthcare Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Llc | 2025-11-19 | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Liver Diseases; Neoplasm Metastasis; Solid tumours | Details |
| Zongertinib | BI-1810631 | Approved | Boehringer Ingelheim International Gmbh | HERNEXEOS, 圣赫途 | United States | Carcinoma, Non-Small-Cell Lung | Boehringer Ingelheim Pharmaceuticals Inc | 2025-08-08 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Liver Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms | Details |
| Pertuzumab biosimilar (Qilu Pharmaceutical) | QL-1209; QL1209 | Approved | Qilu Pharmaceutical Co Ltd | 安赛珠 | Mainland China | Breast Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-12-17 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (AryoGen Pharmed) | Approved | Aryogen Biopharma | AryoTrust | Breast Neoplasms; Stomach Neoplasms | Details | |||||
| Pertuzumab biosimilar (CTTQ) | TQB-2440 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 帕乐坦 | Mainland China | Breast Neoplasms | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2024-12-17 | Breast Neoplasms | Details |
| Disitamab Vedotin | RC-48-ADC; RC48-ADC; RC-48 | Approved | 爱地希, Aidixi | Mainland China | Stomach Neoplasms | RemeGen Co Ltd | 2021-06-08 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Diseases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Genital Diseases, Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Liver Neoplasms; Melanoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Paget Disease, Extramammary; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details | |
| Pyrotinib Maleate | BLTN; HTI-1001; SHR-1258 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Adenocarcinoma; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Glioblastoma; Head and Neck Neoplasms; Liver Diseases; Lung Neoplasms; Mouth Neoplasms; Neoplasm Metastasis; Neoplasms; Penile Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
Product Reviews
M***e2025-03-13
0People LikeGreat pricing and great products! Improvement would be to give open access to the technical information (e.g. protocols and reconstitution details).
G***z2025-03-12 2People LikeWe bought the Her2 to perform SPR to determine the binding affinity of in house produced herceptin. Using the His tag it was easy to capture the protein with amine coupled anti His antibody on the sensor chip surface. Therefore we could prove our antibody has full binding functionality very easily using the biacore T200 system. Ordering and shipping was really simple and all the necessary documentation can be found online. Although I didn't find the CoA in the first place everything was described easily and protocols of different analyses were available.- M***t2025-01-15 2People LikeI used the biotinylated HER2 antigen from ACRO Biosystems for several applications, including phage panning, BLI, and phage ELISA, and it performed very well across all assays. The high purity and specific biotinylation allowed for reliable streptavidin binding, ensuring reproducible results. I have had very good luck with all Acro products during my career in science. Highly recommended for precision-driven workflows!
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to: